Atea Pharmaceuticals, Inc.
AVIR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $351 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $83 | $70 | $62 | $167 |
| Gross Profit | -$83 | -$70 | -$62 | $184 |
| % Margin | – | – | – | 52.4% |
| R&D Expenses | $145 | $133 | $89 | $167 |
| G&A Expenses | $49 | $50 | $49 | $46 |
| SG&A Expenses | $49 | $50 | $49 | $46 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$85 | -$89 | -$69 | -$167 |
| Operating Expenses | $110 | $94 | $68 | $46 |
| Operating Income | -$193 | -$164 | -$131 | $138 |
| % Margin | – | – | – | 39.4% |
| Other Income/Exp. Net | $25 | $29 | $11 | $0 |
| Pre-Tax Income | -$167 | -$135 | -$119 | $139 |
| Tax Expense | $1 | $1 | -$4 | $17 |
| Net Income | -$168 | -$136 | -$116 | $121 |
| % Margin | – | – | – | 34.5% |
| EPS | -2 | -1.63 | -1.39 | 1.46 |
| % Growth | -22.7% | -17.3% | -195.2% | – |
| EPS Diluted | -2 | -1.63 | -1.39 | 1.37 |
| Weighted Avg Shares Out | 84 | 83 | 83 | 83 |
| Weighted Avg Shares Out Dil | 84 | 83 | 83 | 88 |
| Supplemental Information | – | – | – | – |
| Interest Income | $25 | $29 | $11 | $0 |
| Interest Expense | $0 | $0 | $11 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$132 | -$120 | -$111 | $138 |
| % Margin | – | – | – | 39.4% |